|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lopez-Ayllon BD, Moncho-Amor V, Abarrategi
A, Ibañez de Cáceres I, Castro-Carpeño J, Belda-Iniesta C, Perona R
and Sastre L: Cancer stem cells and cisplatin-resistant cells
isolated from non-small-lung cancer cell lines constitute related
cell populations. Cancer Med. 3:1099–1111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen LV, Vanner R, Dirks P and Eaves CJ:
Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143.
2012.PubMed/NCBI
|
|
4
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C and De
Maria R: Identification and expansion of the tumorigenic lung
cancer stem cell population. Cell Death Differ. 15:504–514. 2008.
View Article : Google Scholar
|
|
5
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
6
|
Patrawala L, Calhoun T,
Schneider-Broussard R, Li H, Bhatia B, Tang S, Reilly JG, Chandra
D, Zhou J, Claypool K, et al: Highly purified CD44+
prostate cancer cells from xenograft human tumors are enriched in
tumorigenic and metastatic progenitor cells. Oncogene.
25:1696–1708. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT,
Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, et al: Cisplatin selects
for multidrug-resistant CD133+ cells in lung
adenocarcinoma by activating Notch signaling. Cancer Res.
73:406–416. 2013. View Article : Google Scholar
|
|
9
|
Salnikov AV, Gladkich J, Moldenhauer G,
Volm M, Mattern J and Herr I: CD133 is indicative for a resistance
phenotype but does not represent a prognostic marker for survival
of non-small cell lung cancer patients. Int J Cancer. 126:950–958.
2010.
|
|
10
|
Kitamura H, Okudela K, Yazawa T, Sato H
and Shimoyamada H: Cancer stem cell: Implications in cancer biology
and therapy with special reference to lung cancer. Lung Cancer.
66:275–281. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sterlacci W, Savic S, Fiegl M, Obermann E
and Tzankov A: Putative stem cell markers in non-small-cell lung
cancer: a clinico pathologic characterization. J Thorac Oncol.
9:41–49. 2014. View Article : Google Scholar
|
|
12
|
Tachezy M, Zander H, Wolters-Eisfeld G,
Müller J, Wicklein D, Gebauer F, Izbicki JR and Bockhorn M:
Activated leukocyte cell adhesion molecule (CD166): An ‘inert’
cancer stem cell marker for non-small cell lung cancer? Stem Cells.
32:1429–1436. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yan X, Luo H, Zhou X, Zhu B, Wang Y and
Bian X: Identification of CD90 as a marker for lung cancer stem
cells in A549 and H446 cell lines. Oncol Rep. 30:2733–2740.
2013.PubMed/NCBI
|
|
14
|
Pannuti A, Foreman K, Rizzo P, Osipo C,
Golde T, Osborne B and Miele L: Targeting Notch to target cancer
stem cells. Clin Cancer Res. 16:3141–3152. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Selkoe D and Kopan R: Notch and
Presenilin: Regulated intra-membrane proteolysis links development
and degeneration. Annu Rev Neurosci. 26:565–597. 2003. View Article : Google Scholar
|
|
16
|
Fortini ME: Gamma-secretase-mediated
proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell
Biol. 3:673–684. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hassan KA, Wang L, Korkaya H, Chen G,
Maillard I, Beer DG, Kalemkerian GP and Wicha MS: Notch pathway
activity identifies cells with cancer stem cell-like properties and
correlates with worse survival in lung adenocarcinoma. Clin Cancer
Res. 19:1972–1980. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Arasada RR, Amann JM, Rahman MA, Huppert
SS and Carbone DP: EGFR blockade enriches for lung cancer stem-like
cells through Notch3-dependent signaling. Cancer Res. 74:5572–5584.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Konishi J, Kawaguchi KS, Vo H, Haruki N,
Gonzalez A, Carbone DP and Dang TP: Gamma-secretase inhibitor
prevents Notch3 activation and reduces proliferation in human lung
cancers. Cancer Res. 67:8051–8057. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu YL, Jahangiri A, Delay M and Aghi MK:
Tumor cell autophagy as an adaptive response mediating resistance
to treatments such as antiangiogenic therapy. Cancer Res.
72:4294–4299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mathew R, Karantza-Wadsworth V and White
E: Role of autophagy in cancer. Nat Rev Cancer. 7:961–967. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Z, Li Y, Banerjee S and Sarkar FH:
Emerging role of Notch in stem cells and cancer. Cancer Lett.
279:8–12. 2009. View Article : Google Scholar :
|
|
23
|
Sullivan JP, Spinola M, Dodge M, Raso MG,
Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et
al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma
stem cells dependent on notch signaling. Cancer Res. 70:9937–9948.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Abel EV, Kim EJ, Wu J, Hynes M, Bednar F,
Proctor E, Wang L, Dziubinski ML and Simeone DM: The Notch pathway
is important in maintaining the cancer stem cell population in
pancreatic cancer. PLoS One. 9:e919832014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Grudzien P, Lo S, Albain KS, Robinson P,
Rajan P, Strack PR, Golde TE, Miele L and Foreman KE: Inhibition of
Notch signaling reduces the stem-like population of breast cancer
cells and prevents mammosphere formation. Anticancer Res.
30:3853–3867. 2010.PubMed/NCBI
|
|
26
|
Saito N, Fu J, Zheng S, Yao J, Wang S, Liu
DD, Yuan Y, Sulman EP, Lang FF, Colman H, et al: A high Notch
pathway activation predicts response to γ secretase inhibitors in
proneural subtype of glioma tumor-initiating cells. Stem Cells.
32:301–312. 2014. View Article : Google Scholar :
|
|
27
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andersen S, Donnem T, Al-Saad S, Al-Shibli
K, Stenvold H, Busund LT and Bremnes RM: Correlation and
coexpression of HIFs and NOTCH markers in NSCLC. Anticancer Res.
31:1603–1606. 2011.PubMed/NCBI
|
|
29
|
Westhoff B, Colaluca IN, D'Ario G,
Donzelli M, Tosoni D, Volorio S, Pelosi G, Spaggiari L, Mazzarol G,
Viale G, et al: Alterations of the Notch pathway in lung cancer.
Proc Natl Acad Sci USA. 106:22293–22298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yuan X, Wu H, Xu H, Han N, Chu Q, Yu S,
Chen Y and Wu K: Meta-analysis reveals the correlation of Notch
signaling with non-small cell lung cancer progression and
prognosis. Sci Rep. 5:103382015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Z, Li Y, Ahmad A, Azmi AS, Banerjee
S, Kong D and Sarkar FH: Targeting Notch signaling pathway to
overcome drug resistance for cancer therapy. Biochim Biophys Acta.
1806:258–267. 2010.PubMed/NCBI
|
|
32
|
Shi C, Qian J, Ma M, Zhang Y and Han B:
Notch 3 protein, not its gene polymorphism, is associated with the
chemotherapy response and prognosis of advanced NSCLC patients.
Cell Physiol Biochem. 34:743–752. 2014.PubMed/NCBI
|
|
33
|
Quan YH, Kim B, Park JH, Choi Y, Choi YH
and Kim HK: Highly sensitive and selective anticancer effect by
conjugated HA-cisplatin in non-small cell lung cancer overexpressed
with CD44. Exp Lung Res. 40:475–484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kesharwani RK, Srivastava V, Singh P,
Rizvi SI, Adeppa K and Misra K: A Novel approach for overcoming
drug resistance in breast cancer chemotherapy by targeting new
synthetic curcumin analogues against aldehyde dehydrogenase 1
(ALDH1A1) and glycogen synthase kinase-3 β (GSK-3β). Appl Biochem
Biotechnol. 176:1996–2017. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Green DR and Levine B: To be or not to be?
How selective autophagy and cell death govern cell fate. Cell.
157:65–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
O'Donovan TR, O'Sullivan GC and McKenna
SL: Induction of autophagy by drug-resistant esophageal cancer
cells promotes their survival and recovery following treatment with
chemotherapeutics. Autophagy. 7:509–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu S, Wang X, Chen J and Chen Y: Autophagy
of cancer stem cells is involved with chemoresistance of colon
cancer cells. Biochem Biophys Res Commun. 434:898–903. 2013.
View Article : Google Scholar : PubMed/NCBI
|
